Top Markets
Coin of the day
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

CRVS
주식 순위 #8729
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
주가
$14.07
마지막 동기화: 2026-08-28
시가총액
$1.18B
변동 (1일)
-4.41%
변동 (1년)
145.13%
국가
US
거래 Corvus Pharmaceuticals, Inc. (CRVS)

카테고리

Corvus Pharmaceuticals, Inc. (CRVS)의 주가 이력
최고 종가: $14.55 (2026-08-01 기준)

최저 종가: $14.35 (2016-03-01 기준)
Corvus Pharmaceuticals, Inc.의 주가 이력 (2016 ~ 2026)
연간 주가 성과
연도 성과
2026 (TTM) 52.04%
2025 20.69%
2024 304.94%
2023 86.02%
2022 -68.55%
2021 -28.60%
2020 -6.17%
2019 -13.67%
2018 -53.58%
2017 -32.68%
2016 0.00%
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.53 -12.70%
AU
$138.18 473.58%
US
$759.27 7.20%
CH